Docality.com Logo
 
Dr. Jie  Zhu  Md image

Dr. Jie Zhu Md

100 Biddle Ave Suite 101
Newark DE 19702
302 926-6501
Medical School: Other - 1986
Accepts Medicare: No
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: C1-0007098
NPI: 1457362386
Taxonomy Codes:
208VP0014X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Jie Zhu is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:72148 Description:Mri lumbar spine w/o dye Average Price:$1,716.05 Average Price Allowed
By Medicare:
$353.09
HCPCS Code:62311 Description:Inject spine l/s (cd) Average Price:$700.00 Average Price Allowed
By Medicare:
$88.24
HCPCS Code:64490 Description:Inj paravert f jnt c/t 1 lev Average Price:$450.00 Average Price Allowed
By Medicare:
$111.90
HCPCS Code:64493 Description:Inj paravert f jnt l/s 1 lev Average Price:$420.00 Average Price Allowed
By Medicare:
$94.11
HCPCS Code:95886 Description:Musc test done w/n test comp Average Price:$400.00 Average Price Allowed
By Medicare:
$88.87
HCPCS Code:95870 Description:Muscle test nonparaspinal Average Price:$325.00 Average Price Allowed
By Medicare:
$22.85
HCPCS Code:95934 Description:H-reflex test Average Price:$337.50 Average Price Allowed
By Medicare:
$78.51
HCPCS Code:76942 Description:Echo guide for biopsy Average Price:$465.00 Average Price Allowed
By Medicare:
$211.75
HCPCS Code:95903 Description:Motor nerve conduction test Average Price:$300.00 Average Price Allowed
By Medicare:
$76.57
HCPCS Code:62370 Description:Anl sp inf pmp w/mdreprg&fil Average Price:$350.00 Average Price Allowed
By Medicare:
$132.90
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$375.00 Average Price Allowed
By Medicare:
$161.48
HCPCS Code:95926 Description:Somatosensory testing Average Price:$250.00 Average Price Allowed
By Medicare:
$38.86
HCPCS Code:77003 Description:Fluoroguide for spine inject Average Price:$225.00 Average Price Allowed
By Medicare:
$30.16
HCPCS Code:64491 Description:Inj paravert f jnt c/t 2 lev Average Price:$235.00 Average Price Allowed
By Medicare:
$62.36
HCPCS Code:64492 Description:Inj paravert f jnt c/t 3 lev Average Price:$235.00 Average Price Allowed
By Medicare:
$63.05
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$275.00 Average Price Allowed
By Medicare:
$105.88
HCPCS Code:95904 Description:Sense nerve conduction test Average Price:$225.00 Average Price Allowed
By Medicare:
$58.03
HCPCS Code:20610 Description:Drain/inject joint/bursa Average Price:$237.50 Average Price Allowed
By Medicare:
$72.28
HCPCS Code:64494 Description:Inj paravert f jnt l/s 2 lev Average Price:$215.00 Average Price Allowed
By Medicare:
$52.77
HCPCS Code:64495 Description:Inj paravert f jnt l/s 3 lev Average Price:$215.00 Average Price Allowed
By Medicare:
$53.82
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$250.00 Average Price Allowed
By Medicare:
$105.09
HCPCS Code:99223 Description:Initial hospital care Average Price:$299.11 Average Price Allowed
By Medicare:
$195.87
HCPCS Code:G0434 Description:Drug screen multi drug class Average Price:$123.11 Average Price Allowed
By Medicare:
$20.60
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$125.00 Average Price Allowed
By Medicare:
$43.10
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$150.00 Average Price Allowed
By Medicare:
$71.11
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$80.00 Average Price Allowed
By Medicare:
$19.32
HCPCS Code:97110 Description:Therapeutic exercises Average Price:$85.00 Average Price Allowed
By Medicare:
$28.84
HCPCS Code:97140 Description:Manual therapy Average Price:$80.00 Average Price Allowed
By Medicare:
$26.30
HCPCS Code:99211 Description:Office/outpatient visit est Average Price:$60.00 Average Price Allowed
By Medicare:
$20.07
HCPCS Code:82570 Description:Assay of urine creatinine Average Price:$30.00 Average Price Allowed
By Medicare:
$6.44
HCPCS Code:36415 Description:Routine venipuncture Average Price:$20.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:81025 Description:Urine pregnancy test Average Price:$25.00 Average Price Allowed
By Medicare:
$8.96
HCPCS Code:J3301 Description:Triamcinolone acet inj NOS Average Price:$15.00 Average Price Allowed
By Medicare:
$1.69
HCPCS Code:A4220 Description:Infusion pump refill kit Average Price:$50.00 Average Price Allowed
By Medicare:
$49.86
HCPCS Code:97760 Description:Orthotic mgmt and training Average Price:$35.00 Average Price Allowed
By Medicare:
$34.98

HCPCS Code Definitions

64493
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level
A4220
Refill kit for implantable infusion pump
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
77003
Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid)
76942
Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation
G0434
Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
64492
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
64494
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)
64491
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure)
62311
Injection(s), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, includes contrast for localization when performed, epidural or subarachnoid; lumbar or sacral (caudal)
20610
Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
64490
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level
62370
Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional)
95886
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels (List separately in addition to code for primary procedure)
72148
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material
95870
Needle electromyography; limited study of muscles in 1 extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99211
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.
95926
Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs
64495
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)
99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
97760
Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes
97140
Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
97110
Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1396703351
Pulmonary Disease
1,397
1245231638
Diagnostic Radiology
1,048
1306888516
Diagnostic Radiology
777
1083726053
Diagnostic Radiology
690
1962422469
Pulmonary Disease
611
1437197480
Diagnostic Radiology
522
1427008622
Medical Oncology
507
1144229345
Cardiac Electrophysiology
467
1629053046
General Surgery
435
1467553982
Cardiovascular Disease (Cardiology)
400
*These referrals represent the top 10 that Dr. Zhu has made to other doctors

Publications

Suppression of Kv1.5 protects against endothelial apoptosis induced by palmitate and in type 2 diabetes mice. - Life sciences
Palmitate, a common saturated free fatty acid, induces endothelial apoptosis in vitro in culture endothelial cells and in vivo in type 2 diabetes mellitus (T2DM) patients. The present study aimed to investigate whether Kv1.5 regulates palmitate-induced endothelial apoptosis and endothelial dysfunction in T2DM.In vitro experiments were carried out in primary human HUVECs. Apoptosis was analyzed by flow cytometry. Cell viability was determined by Cell Counting Assay Kit-8. The siRNA transfection was employed to knockdown Kv1.5 protein expression. Intracellular and mitochondrial ROS, and mitochondrial membrane potential were detected using fluorescent probes. Male C57BL/6 mice fed with high-sucrose/fat diet were injected with streptozotocin (35mg/kg body weight) to establish T2DM animal model.We found that palmitate-induced endothelial apoptosis was parallel to a significant increase in endogenous Kv1.5 protein expression in endothelial cells. Silencing of Kv1.5 with siRNA reduced palmitate-induced endothelial apoptosis, intracellular ROS generation, mitochondrial ROS generation and membrane potential (Δψm) alteration and cleaved caspase-3 protein expression; while increased cell viability and ratio of Bcl-2/Bax. Furthermore, we observed that Kv1.5 protein expression increased in endothelial cells of thoracic aorta of T2DM mice. Silencing of Kv1.5 significantly improved the endothelium-dependent vasodilation in thoracic aortic rings of T2DM mice.These results demonstrate that suppression of Kv1.5 protects endothelial cells against palmitate-induced apoptosis via inhibiting mitochondria-mediated excessive ROS generation and apoptotic signaling pathway, suggesting that Kv1.5 may serve as a therapeutic target of treatment for endothelial dysfunction induced by palmitate and lipid metabolism in T2DM patients.Copyright © 2015. Published by Elsevier Inc.
Effects of ultrasound, CaCl2 and STPP on the ultrastructure of the milk goat longissimus muscle fiber observed with atomic force microscopy. - Scanning
The aim of this study was to analyze the effects of ultrasound bath intensity, CaCl2 and sodium tripolyphosphate (STPP) concentration on the ultrastructure of longissimus muscle fiber from milk goats. The sarcomere length was measured by atomic force microscopy. According to the results of AFM images, the sarcomere length is longest when the conditions were an intensity of 100 W ultrasound bath (42.77% increment), a concentration of 300 mM CaCl2 injection (44.68% increment) or 90 mM STPP injection (19.41% increment). Apart from the sarcomere length, the study put forward a potential index (roughness) to represent tenderness of meat which was treated by ultrasound bath. Among different methods, ultrasound bath was chosen as the preferred tenderization method. SCANNING 9999:1-9, 2016. © 2016 Wiley Periodicals, Inc.© Wiley Periodicals, Inc.
Homocysteine induces cardiac hypertrophy by up-regulating ATP7a expression. - International journal of clinical and experimental pathology
The aim of the study is to investigate the molecular mechanism by which homocysteine (Hcy) induces cardiac hypertrophy.Primary cardiomyocytes were obtained from baby Sprague-Dawley rats within 3 days after birth. Flow cytometry was used to measure cell sizes. Quantitative real-time polymerase chain reaction was performed to measure the expression of β-myosin heavy chain and atrial natriuretic peptide genes. Western blotting assay was employed to determine ATP7a protein expression. Cytochrome C oxidase (COX) activity test was used to evaluate the activity of COX. Atomic absorption spectroscopy was performed to determine copper content. siRNAs were used to target-silence the expression of ATP7a.Hcy induced cardiac hypertrophy and increased the expression of cardiac hypertrophy-related genes. ATP7a was a key factor in cardiac hypertrophy induced by Hcy. Reduced ATP7a expression inhibited cardiac hypertrophy induced by Hcy. Elevated ATP7a expression induced by Hcy inhibited COX activity. Enhanced ATP7a expression inhibited COX activity by lowering intracellular copper content.Hcy elevates ATP7a protein expression, reduces copper content, and lowers COX activity, finally leading to cardiac hypertrophy.
Robot-assisted Laparoscopic Inferior Vena Cava Thrombectomy: Different Sides Require Different Techniques. - European urology
The safety and feasibility of robot-assisted laparoscopic inferior vena cava (IVC) thrombectomy (RAL-IVCTE) have been investigated in limited reports.To share our initial experience with RAL-IVCTE, as well as describe respectively the detailed techniques for RAL-IVCTE for left or right renal cell carcinoma (RCC).From May 2013 to July 2014, 17 patients with RCC involving IVC tumor thrombus were admitted to our hospital.For right RCC, the caudal IVC, left renal vein, and cephalic IVC were sequentially clamped. The IVC wall was cut, and the thrombus was removed. For left RCC, the left renal vein, which included the thrombus, was ligated with Endo-GIA. The caudal IVC, right renal artery, right renal vein, and cephalic IVC were sequentially clamped.The detailed techniques for RAL-IVCTE for different sides were described and the perioperative outcomes recorded.The operations were successfully performed without open conversion. Median operation time was 131min (100-150min) and 250min (190-275min) for the right and left RCC, respectively. Median estimated blood loss was 240ml (145-320ml). Median IVC blocking time was 17min (12-25min). For left RCC, median warm ischemia time for the right kidney was 18min (14-22min). A grade IV complication-bleeding from tributaries of the IVC-developed in one case and was successfully resolved with intraoperative endoscopic suture.RAL-IVCTE is safe and feasible. For left RCC involving IVC thrombus, right renal warm ischemia time is necessary during the procedure, requiring a more advanced technical skill. The therapeutic effect and overall survival rate require further investigation with a larger sample size and longer follow-up.Robot-assisted laparoscopic inferior vena cava thrombectomy is technically challenging but safe and feasible. The therapeutic effect needs further investigation.Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
[Effect of enhanced green fluorescent protein fusion on Ano1 physiological feature]. - Sheng li xue bao : [Acta physiologica Sinica]
The aim of the present study was to investigate whether the physiological features of Ano1 were affected by enhanced green fluorescent protein (EGFP) fusing at Ano1 C-terminal. The eukaryotic expression vectors of Ano1 and EGFP-Ano1 were constructed, and these plasmids were transfected into Fischer rat thyroid follicular epithelial (FRT) cells using liposome. The expression and location of Ano1 were examined by using inverted fluorescence microscope. The ability of Ano1 to transport iodide was detected by kinetics experiment of fluorescence quenching. The results showed that both Ano1 and EGFP-Ano1 were expressed on FRT cell membrane and could be activated by Ca(2+). There was no significant difference of the ability to transport iodide between Ano1 and EGFP-Ano1. These results suggest Ano1 and EGFP-Ano1 have similar physiological feature.
RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. - Nature communications
In animal models, resident memory CD8+ T (Trm) cells assist in respiratory virus elimination but their importance in man has not been determined. Here, using experimental human respiratory syncytial virus (RSV) infection, we investigate systemic and local virus-specific CD8+ T-cell responses in adult volunteers. Having defined the immunodominance hierarchy, we analyse phenotype and function longitudinally in blood and by serial bronchoscopy. Despite rapid clinical recovery, we note surprisingly extensive lower airway inflammation with persistent viral antigen and cellular infiltrates. Pulmonary virus-specific CD8+ T cells display a CD69+CD103+ Trm phenotype and accumulate to strikingly high frequencies into convalescence without continued proliferation. While these have a more highly differentiated phenotype, they express fewer cytotoxicity markers than in blood. Nevertheless, their abundance before infection correlates with reduced symptoms and viral load, implying that CD8+ Trm cells in the human lung can confer protection against severe respiratory viral disease when humoral immunity is overcome.
Fasting Glucose Levels Correlate with Disease Severity of Guillain-Barré Syndrome. - PloS one
A potential association between diabetes and Guillain-Barré syndrome (GBS) has been indicated by a few case studies. We retrospectively analyzed the clinical features of a large cohort of GBS patients to explore the relationship between the level of fasting plasma glucose (FPG) obtained in the acute phase at admission and the severity of GBS.Three hundred and four GBS patients were divided into two groups, one with normal FPG and the other with high FPG levels according to the international standards of FPG.The GBS disability scale score was positively, the Medical Research Council (MRC) sum score was negatively correlated to the level of FPG, but not to blood HBA1c or CSF glucose concentrations. A relatively higher FPG level was observed in older and younger GBS patients, and more often in those with cranial nerve involvement, autonomic deficit, dyspnea and ventilator dependence than in patients without these clinical characteristics. Importantly, higher levels of FPG at admission were associated with poorer short-term prognosis measured by the MRC sum score and the GBS disability scale at discharge.Our data demonstrates that FPG in the acute phase of GBS correlates with the severity of GBS and may predict the short-term prognosis of GBS.
Gold Nanoparticles Deposited Polyaniline-TiO2 Nanotube for Surface Plasmon Resonance Enhanced Photoelectrochemical Biosensing. - ACS applied materials & interfaces
A novel ternary composite composed of TiO2 nanotubes (TiONTs), polyaniline (PANI), and gold nanoparticles (GNPs) was prepared for photoelectrochemical (PEC) biosensing. PANI was initially coated on TiONTs with an oxidative polymerization method, and 12-phosphotungstic acid was then used as a highly localized photoactive reducing agent to deposit GNPs on TiONT-PANI. The morphology and composition of the composite were characterized by various spectroscopic and microscopic methods. Electrochemical impedance spectroscopy was also conducted to demonstrate the excellent electrical conductivity of the composite. A PEC biosensor was fabricated by immobilizing a mixture of lactate dehydrogenase and the composite onto ITO electrodes, which regenerated nicotinamide adenine dinucleotide (NAD(+)) to complete the enzymatic cycle and led to an improved method for PEC detection of lactate. Because of the surface plasmon resonance enhanced effect of GNPs, the electrochromic performance of PANI, and excellent conductivity and biocompatibility of the composite, this method showed a dynamic range of 0.5-210 μM, sensitivity of 0.0401 μA μM(-1), and a detection limit of 0.15 μM.
Ankaflavin ameliorates steatotic liver ischemia-reperfusion injury in mice. - Hepatobiliary & pancreatic diseases international : HBPD INT
It is well-known that steatotic liver is more susceptible to ischemia-reperfusion (I/R) injury during liver transplantation, liver resection and other liver surgeries. The increasing incidence of non-alcoholic fatty liver disease (NAFLD) decreases the availability of liver donors. Although steatotic liver is now accepted as a source of liver for transplantation, NAFLD exacerbates the liver injury after liver surgery. The present study was to investigate the protective role of ankaflavin in steatotic liver I/R injury.The model of fatty liver mice was induced with high fat diet in four weeks, ankaflavin or vehicle (saline) was administrated by gavage once a day for one week. The animals were subjected to partial hepatic I/R. Blood samples were collected to measure serum aminotransferases. The liver tissues were used to examine liver steatosis, apoptosis of hepatocytes, hepatic oxidative stress, Kupffer cells and inflammatory cytokines. The effects of ankaflavin on inflammatory cytokines were evaluated in isolated Kupffer cells from the steatotic liver.Ankaflavin reduced liver steatosis in high fat diet mice. Compared with normal mice, I/R induced more damage to the mice with steatosis, such as hepatocyte apoptosis, inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta), serum aminotransferases and thiobarbituric acid reactive substances. Importantly, ankaflavin administration significantly attenuated these changes. In addition, ankaflavin significantly decreased the proliferation of Kupffer cells and the expression of TNF-alpha, IL-6 and IL-1beta protein in isolated Kupffer cells stimulated by TNF-alpha.Ankaflavin has protective effects against I/R injury through anti-inflammatory, anti-oxidant and anti-apoptotic mechanisms in fatty livers, these effects are at least partially mediated by inhibiting Kupffer cell functions.
Maize rea1 mutant stimulates ribosome use efficiency and triggers distinct transcriptional and translational responses. - Plant physiology
Ribosome biogenesis is a fundamental cellular process in all cells. Impaired ribosome biogenesis causes developmental defects; however, its molecular and cellular basis is not fully understood. We cloned a gene responsible for a maize small seed mutant dek*, and found it encodes Ribosome export associated 1 (ZmRea1). Rea1 is an AAA-ATPase that controls 60S ribosome export from the nucleus to the cytoplasm after ribosome maturation. dek* is a weak mutant allele with decreased Rea1 function. In dek* cells, mature 60S ribosome subunits are reduced in the nucleus and cytoplasm, but the proportion of actively translating polyribosomes in cytosol is significantly increased. Reduced phosphorylation of eIF2α and the increased eEF1α level indicate an enhancement of general translational efficiency in dek* cells. The mutation also triggers dramatic changes in differentially transcribed genes (DTGs) and differentially translated RNAs (DTRs). Discrepancy was observed between DTGs and DTRs, indicating distinct cellular responses at transcription and translation levels to the stress of defective ribosome processing. DNA replication and nucleosome assembly related gene expression are selectively suppressed at translational level, resulting in inhibited cell growth and proliferation in dek* cells. This study provides insight into cellular responses due to impaired ribosome biogenesis.© 2015 American Society of Plant Biologists. All rights reserved.

Map & Directions

100 Biddle Ave Suite 101 Newark, DE 19702
View Directions In Google Maps

Nearby Doctors

38 Peoples Plz
Newark, DE 19702
302 344-4000
Nemours Pediatrics Peoples Plaza 1400 Peoples Plaza Suite 300
Newark, DE 19702
302 367-7820
260 Chapman Rd Suite 100 E
Newark, DE 19702
302 921-1914
1400 Peoples Plz Suite 204
Newark, DE 19702
302 321-1282
2600 Glasgow Ave Suite 124
Newark, DE 19702
302 364-4200
18 Capano Drive Apt C4
Newark, DE 19702
302 928-8693
100 Peoples Plz
Newark, DE 19702
302 925-5600
300 Christiana Medical Ctr
Newark, DE 19702
302 310-0869
100 Christiana Village Professional Ctr
Newark, DE 19702
302 383-3666